<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00589654</url>
  </required_header>
  <id_info>
    <org_study_id>97-127</org_study_id>
    <secondary_id>DAMD17966292</secondary_id>
    <nct_id>NCT00589654</nct_id>
  </id_info>
  <brief_title>Menstrual Cycle Maintenance and Quality of Life: A Prospective Study</brief_title>
  <official_title>Menstrual Cycle Maintenance and Quality of Life: A Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      Very little is known about the incidence, onset, time course, and symptomatology of premature
      menopause induced by breast cancer therapy. No prospective study exists. The purpose of the
      present study is to identify determinants of treatment-related amenorrhea nad its effect on
      quality of life in a cohort of youg breast cancer patients.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 1997</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The overall goal of the proposed research is to recruit and follow young breast cancer patients aged 45 and younger, in order to examine menstrual cycle maintenance.</measure>
    <time_frame>Conclusion of the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Examine possible predictors of treatment-related amenorrhea including age, smoking history, race, and treatment variables</measure>
    <time_frame>Conclusion of study</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">810</enrollment>
  <condition>Amenorrhea</condition>
  <condition>Menstrual Cycle</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire</intervention_name>
    <description>Data collection instruments will be obtained at baseline and every six months. Follow-up will range between 26-42 months for participants.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Stage 1-3 breast cancer patients 18-45 years of age will be identified. Those with normal
        menstrual cycles will be eligible.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-institutional (community dwelling) woman of any race

          -  Between 18-45 years at the first screening visit

          -  Have regular menstrual cycles

          -  Diagnosed with invasive breast cancer stage I, II, III within the previous eight
             months

          -  Have physician agreement for patient participation

        Exclusion Criteria:

          -  No menstrual bleeding cycles

          -  Psychiatric or psychologic abnormality precluding the informed consent process or
             which would decrease compliance

          -  Previous malignancy (excepting basal and squamous skin cancer and stage 0 cervical
             cancer)

          -  Stage IV breast malignancy

          -  Residency outside United States

          -  No telephone
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kimberly Van Zee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 26, 2007</study_first_submitted>
  <study_first_submitted_qc>January 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2008</study_first_posted>
  <last_update_submitted>January 2, 2018</last_update_submitted>
  <last_update_submitted_qc>January 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>amenorrhea</keyword>
  <keyword>menstrual cycle</keyword>
  <keyword>Breast cancer</keyword>
  <keyword>questionnaire</keyword>
  <keyword>97-127</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amenorrhea</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

